Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition
Yearbook of Paediatric Endocrinology · 30.09.2025
DOI: 10.1530/ey.22.5.9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Yearbook of Paediatric Endocrinology, online erschienen am 30.09.2025. Verfasst von Kim AS und 14 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
AS, K., VE, T., A, C., S, D., A, Z., ST, M., Y, X., MK, S., A, P., J, C., TL, C., PI, C., JR, C., CM, G., & MM, M. (2025). Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition. Yearbook of Paediatric Endocrinology. https://doi.org/10.1530/ey.22.5.9
Vancouver
AS K, VE T, A C, S D, A Z, ST M, et al. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition. Yearbook of Paediatric Endocrinology. 2025. doi:10.1530/ey.22.5.9
BibTeX
@article{AS2025,
author = {AS, Kim and VE, Taylor and A, Castro-Martinez and S, Dhakal and A, Zamerli and ST, Mohanty and Y, Xiao and MK, Simic and A, Pantalone and J, Chu and TL, Cheng and PI, Croucher and JR, Center and CM, Girgis and MM, McDonald},
title = {Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition},
journal = {Yearbook of Paediatric Endocrinology},
year = {2025},
doi = {10.1530/ey.22.5.9}
}
EUVIMED